It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pten is one of the most frequently mutated tumour suppressor gene in cancer. PTEN is generally altered in invasive cancers such as glioblastomas, but its function in collective cell migration and invasion is not fully characterised. Herein, we report that the loss of PTEN increases cell speed during collective migration of non-tumourous cells both in vitro and in vivo. We further show that loss of PTEN promotes LKB1-dependent phosphorylation and activation of the major metabolic regulator AMPK. In turn AMPK increases VASP phosphorylation, reduces VASP localisation at cell-cell junctions and decreases the interjunctional transverse actin arcs at the leading front, provoking a weakening of cell-cell contacts and increasing migration speed. Targeting AMPK activity not only slows down PTEN-depleted cells, it also limits PTEN-null glioblastoma cell invasion, opening new opportunities to treat glioblastoma lethal invasiveness.
Pten is a tumour suppressor gene that is associated with highly invasive cancers such as glioblastoma. Here the authors show that PTEN loss results in increased migratory behaviour, which can be countered by targeting AMPK activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Institut Pasteur, CNRS UMR3691, Université Paris Cité, Équipe Labellisée Ligue Contre le Cancer, Cell Polarity, Migration and Cancer Unit, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)
2 Institut Pasteur, CNRS UMR3691, Université Paris Cité, Équipe Labellisée Ligue Contre le Cancer, Cell Polarity, Migration and Cancer Unit, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535); Sorbonne Université, Collège doctoral, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657)
3 Institut Pasteur, CNRS UMR3738, Macrophages and Development of Immunity Unit, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)
4 Inserm U1127, CNRS UMR7225, Sorbonne Universités, UPMC University Paris 04 UMR S1127, Institut du Cerveau, ICM, Paris, France (GRID:grid.411439.a) (ISNI:0000 0001 2150 9058)
5 Uppsala University, Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
6 Institut Pasteur, CNRS UMR3691, Université Paris Cité, Équipe Labellisée Ligue Contre le Cancer, Cell Polarity, Migration and Cancer Unit, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535); Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS UMR7622, Paris, France (GRID:grid.503253.2) (ISNI:0000 0004 0520 7190)